Cargando…

Bioinformatics and network-based screening and discovery of potential molecular targets and small molecular drugs for breast cancer

Accurate identification of molecular targets of disease plays an important role in diagnosis, prognosis, and therapies. Breast cancer (BC) is one of the most common malignant cancers in women worldwide. Thus, the objective of this study was to accurately identify a set of molecular targets and small...

Descripción completa

Detalles Bibliográficos
Autores principales: Alam, Md Shahin, Sultana, Adiba, Sun, Hongyang, Wu, Jin, Guo, Fanfan, Li, Qing, Ren, Haigang, Hao, Zongbing, Zhang, Yi, Wang, Guanghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531711/
https://www.ncbi.nlm.nih.gov/pubmed/36204232
http://dx.doi.org/10.3389/fphar.2022.942126
_version_ 1784801958989660160
author Alam, Md Shahin
Sultana, Adiba
Sun, Hongyang
Wu, Jin
Guo, Fanfan
Li, Qing
Ren, Haigang
Hao, Zongbing
Zhang, Yi
Wang, Guanghui
author_facet Alam, Md Shahin
Sultana, Adiba
Sun, Hongyang
Wu, Jin
Guo, Fanfan
Li, Qing
Ren, Haigang
Hao, Zongbing
Zhang, Yi
Wang, Guanghui
author_sort Alam, Md Shahin
collection PubMed
description Accurate identification of molecular targets of disease plays an important role in diagnosis, prognosis, and therapies. Breast cancer (BC) is one of the most common malignant cancers in women worldwide. Thus, the objective of this study was to accurately identify a set of molecular targets and small molecular drugs that might be effective for BC diagnosis, prognosis, and therapies, by using existing bioinformatics and network-based approaches. Nine gene expression profiles (GSE54002, GSE29431, GSE124646, GSE42568, GSE45827, GSE10810, GSE65216, GSE36295, and GSE109169) collected from the Gene Expression Omnibus (GEO) database were used for bioinformatics analysis in this study. Two packages, LIMMA and clusterProfiler, in R were used to identify overlapping differential expressed genes (oDEGs) and significant GO and KEGG enrichment terms. We constructed a PPI (protein–protein interaction) network through the STRING database and identified eight key genes (KGs) EGFR, FN1, EZH2, MET, CDK1, AURKA, TOP2A, and BIRC5 by using six topological measures, betweenness, closeness, eccentricity, degree, MCC, and MNC, in the Analyze Network tool in Cytoscape. Three online databases GSCALite, Network Analyst, and GEPIA were used to analyze drug enrichment, regulatory interaction networks, and gene expression levels of KGs. We checked the prognostic power of KGs through the prediction model using the popular machine learning algorithm support vector machine (SVM). We suggested four TFs (TP63, MYC, SOX2, and KDM5B) and four miRNAs (hsa-mir-16-5p, hsa-mir-34a-5p, hsa-mir-1-3p, and hsa-mir-23b-3p) as key transcriptional and posttranscriptional regulators of KGs. Finally, we proposed 16 candidate repurposing drugs YM201636, masitinib, SB590885, GSK1070916, GSK2126458, ZSTK474, dasatinib, fedratinib, dabrafenib, methotrexate, trametinib, tubastatin A, BIX02189, CP466722, afatinib, and belinostat for BC through molecular docking analysis. Using BC cell lines, we validated that masitinib inhibits the mTOR signaling pathway and induces apoptotic cell death. Therefore, the proposed results might play an effective role in the treatment of BC patients.
format Online
Article
Text
id pubmed-9531711
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95317112022-10-05 Bioinformatics and network-based screening and discovery of potential molecular targets and small molecular drugs for breast cancer Alam, Md Shahin Sultana, Adiba Sun, Hongyang Wu, Jin Guo, Fanfan Li, Qing Ren, Haigang Hao, Zongbing Zhang, Yi Wang, Guanghui Front Pharmacol Pharmacology Accurate identification of molecular targets of disease plays an important role in diagnosis, prognosis, and therapies. Breast cancer (BC) is one of the most common malignant cancers in women worldwide. Thus, the objective of this study was to accurately identify a set of molecular targets and small molecular drugs that might be effective for BC diagnosis, prognosis, and therapies, by using existing bioinformatics and network-based approaches. Nine gene expression profiles (GSE54002, GSE29431, GSE124646, GSE42568, GSE45827, GSE10810, GSE65216, GSE36295, and GSE109169) collected from the Gene Expression Omnibus (GEO) database were used for bioinformatics analysis in this study. Two packages, LIMMA and clusterProfiler, in R were used to identify overlapping differential expressed genes (oDEGs) and significant GO and KEGG enrichment terms. We constructed a PPI (protein–protein interaction) network through the STRING database and identified eight key genes (KGs) EGFR, FN1, EZH2, MET, CDK1, AURKA, TOP2A, and BIRC5 by using six topological measures, betweenness, closeness, eccentricity, degree, MCC, and MNC, in the Analyze Network tool in Cytoscape. Three online databases GSCALite, Network Analyst, and GEPIA were used to analyze drug enrichment, regulatory interaction networks, and gene expression levels of KGs. We checked the prognostic power of KGs through the prediction model using the popular machine learning algorithm support vector machine (SVM). We suggested four TFs (TP63, MYC, SOX2, and KDM5B) and four miRNAs (hsa-mir-16-5p, hsa-mir-34a-5p, hsa-mir-1-3p, and hsa-mir-23b-3p) as key transcriptional and posttranscriptional regulators of KGs. Finally, we proposed 16 candidate repurposing drugs YM201636, masitinib, SB590885, GSK1070916, GSK2126458, ZSTK474, dasatinib, fedratinib, dabrafenib, methotrexate, trametinib, tubastatin A, BIX02189, CP466722, afatinib, and belinostat for BC through molecular docking analysis. Using BC cell lines, we validated that masitinib inhibits the mTOR signaling pathway and induces apoptotic cell death. Therefore, the proposed results might play an effective role in the treatment of BC patients. Frontiers Media S.A. 2022-09-20 /pmc/articles/PMC9531711/ /pubmed/36204232 http://dx.doi.org/10.3389/fphar.2022.942126 Text en Copyright © 2022 Alam, Sultana, Sun, Wu, Guo, Li, Ren, Hao, Zhang and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Alam, Md Shahin
Sultana, Adiba
Sun, Hongyang
Wu, Jin
Guo, Fanfan
Li, Qing
Ren, Haigang
Hao, Zongbing
Zhang, Yi
Wang, Guanghui
Bioinformatics and network-based screening and discovery of potential molecular targets and small molecular drugs for breast cancer
title Bioinformatics and network-based screening and discovery of potential molecular targets and small molecular drugs for breast cancer
title_full Bioinformatics and network-based screening and discovery of potential molecular targets and small molecular drugs for breast cancer
title_fullStr Bioinformatics and network-based screening and discovery of potential molecular targets and small molecular drugs for breast cancer
title_full_unstemmed Bioinformatics and network-based screening and discovery of potential molecular targets and small molecular drugs for breast cancer
title_short Bioinformatics and network-based screening and discovery of potential molecular targets and small molecular drugs for breast cancer
title_sort bioinformatics and network-based screening and discovery of potential molecular targets and small molecular drugs for breast cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531711/
https://www.ncbi.nlm.nih.gov/pubmed/36204232
http://dx.doi.org/10.3389/fphar.2022.942126
work_keys_str_mv AT alammdshahin bioinformaticsandnetworkbasedscreeninganddiscoveryofpotentialmoleculartargetsandsmallmoleculardrugsforbreastcancer
AT sultanaadiba bioinformaticsandnetworkbasedscreeninganddiscoveryofpotentialmoleculartargetsandsmallmoleculardrugsforbreastcancer
AT sunhongyang bioinformaticsandnetworkbasedscreeninganddiscoveryofpotentialmoleculartargetsandsmallmoleculardrugsforbreastcancer
AT wujin bioinformaticsandnetworkbasedscreeninganddiscoveryofpotentialmoleculartargetsandsmallmoleculardrugsforbreastcancer
AT guofanfan bioinformaticsandnetworkbasedscreeninganddiscoveryofpotentialmoleculartargetsandsmallmoleculardrugsforbreastcancer
AT liqing bioinformaticsandnetworkbasedscreeninganddiscoveryofpotentialmoleculartargetsandsmallmoleculardrugsforbreastcancer
AT renhaigang bioinformaticsandnetworkbasedscreeninganddiscoveryofpotentialmoleculartargetsandsmallmoleculardrugsforbreastcancer
AT haozongbing bioinformaticsandnetworkbasedscreeninganddiscoveryofpotentialmoleculartargetsandsmallmoleculardrugsforbreastcancer
AT zhangyi bioinformaticsandnetworkbasedscreeninganddiscoveryofpotentialmoleculartargetsandsmallmoleculardrugsforbreastcancer
AT wangguanghui bioinformaticsandnetworkbasedscreeninganddiscoveryofpotentialmoleculartargetsandsmallmoleculardrugsforbreastcancer